Indaptus Therapeutics is trading 10.08% down at $1.07, with no confirmed company-specific announcement identified for August 12, 2026.
- Search results show only an unconfirmed estimated earnings window of August 12–14, not a company-announced report date.
- Broader markets are modestly higher, so the decline is not clearly explained by market-wide weakness.
- The immediate catalyst remains unclear; delayed filings or announcements should be rechecked.